Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Shares Outstanding (Diluted Average) (2016 - 2025)

Lifecore Biomedical, Inc. \De\ (LFCR) has 14 years of Shares Outstanding (Diluted Average) data on record, last reported at $34.8 million in Q2 2025.

  • For Q2 2025, Shares Outstanding (Diluted Average) fell 5.02% year-over-year to $34.8 million; the TTM value through May 2025 reached $34.8 million, down 5.02%, while the annual FY2025 figure was $34.8 million, 5.02% down from the prior year.
  • Shares Outstanding (Diluted Average) reached $34.8 million in Q2 2025 per LFCR's latest filing, up from $34.1 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $36.7 million in Q2 2024 and bottomed at $29.3 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $31.6 million, with a median of $30.1 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Diluted Average): rose 22.94% in 2023, then decreased 10.41% in 2024.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $29.5 million in 2021, then rose by 0.45% to $29.6 million in 2022, then grew by 22.94% to $36.4 million in 2023, then dropped by 10.41% to $32.6 million in 2024, then increased by 6.77% to $34.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Diluted Average) were $34.8 million in Q2 2025, $34.1 million in Q1 2025, and $32.6 million in Q4 2024.